Uncontrolled-rate freezing techniques represent an attractive alternative to controlled-rate cryopreservation procedures which are time-consuming and require high-level technical expertise. In this study, we report our experience using uncontrolled-rate cryopreservation and mechanical freezer storage at −140؇C. /l white blood cells and 50 ؋ 10 9 /l platelets were 9 and 13, respectively. In conclusion, the procedure described here is characterized by short execution time, allows a substantial recovery of primitive and committed progenitors and is associated with prompt hematopoietic recovery following myeloablative therapy even after long-term storage.
The capacity of mobilized peripheral blood progenitor cells (PBPC) to reconstitute hematopoietic function following myeloablative therapy has been demonstrated both in the autologous and the allogeneic settings. [1] [2] [3] According to current therapeutic strategies, cryopreservation of hematopoietic cells is required for virtually all autologous and some allogeneic blood cell transplants. Freezing and storage conditions capable of either preventing or limiting the functional damage of hematopoietic cells are crucial prerequisites to guarantee the maintenance of stem/progenitor cell reconstituting activity on a long-term basis. 4 Several cryopreservation techniques are used by different transplant centers and no general consensus has so far been achieved on optimal freezing conditions.
Hematopoietic cells are cryopreserved in media supplemented with dimethylsulfoxide (DMSO), as an intracellular cryoprotectant, plus either human serum albumin (HSA), plasma, serum or oxypolygelatine with or without hydroxyethylstarch (HES), as extracellular cryoprotectants. 5 Cryopreservation is usually performed according to controlled-rate methods, which are time-consuming procedures requiring computer-assisted devices that allow a progressive temperature reduction of the material to be frozen. Controlled-rate freezing is followed by storage of hematopoietic cells in either liquid or vapor phase of nitrogen. The expanding indication of high-dose chemotherapy followed by blood cell transplants is associated with an exponentially growing request for PBPC collection, cryopreservation and storage. These issues strongly support methodological improvements aimed at cost reduction and facilitation of routine freezing procedures. [6] [7] [8] Distinct subsets of stem cells may be responsible for different phases of engraftment after stem cell transplantation. 9, 10 In vitro assessment of the engraftment potential of hematopoietic cells can be achieved by means of shortterm culture assays, evaluating committed hematopoietic progenitors, as well as the long-term culture-initiating cell (LTC-IC) assay which measures a primitive, self-renewing progenitor capable of initiating and sustaining hematopoiesis for weeks in culture. 11, 12 Recent evidence has demonstrated that the LTC-IC assay detects a class of primitive stem cells with phenotypic characteristics of transplantable murine in vivo repopulating cells 13 and self-renewal potential.
14 However, the role of primitive LTC-IC in promoting hematopoietic recovery following hematopoietic cell transplantation as well as the dose of these progenitors which is required for a prompt and durable engraftment is still a matter of controversy. Despite the availability of in vitro assays allowing analysis of the quantitative and qualitative clonogenic potential of a given hematopoietic cell suspension, evaluation of the engraftment potential of cryopreserved hematopoietic cells still relies on evidence of hematopoietic reconstitution following high-dose chemotherapy.
In the present study, we report our experience using uncontrolled-rate freezing in a cryoprotectant solution consisting of HSA and DMSO followed by mechanical freezer storage at −140°C. Quality controls used to test the effects of uncontrolled-rate freezing involved analysis of primitive progenitors, which were quantitated by means of the LTC-IC assay, as well as committed progenitors, ie, multilineage colony-forming units (CFU-MIX), erythroid burst-forming units (BFU-E) and granulocyte-macrophage colony-forming units (CFU-GM). In addition, the capacity of uncontrolled-rate cryopreserved PBPC in reconstituting hematopoiesis following myeloablative chemotherapy was analyzed in 14 patients.
Materials and methods

Patients, mobilization regimens and harvesting criteria
Twenty-three patients (10 males, 13 females) with a median age of 54 years (range 6-62) and a diagnosis of Hodgkin'sdisease (n = 4), non-Hodgkin lymphoma (n = 7) and multiple myeloma (n = 12) underwent PBPC mobilization with either G-CSF (5 g/kg/day) after cyclophosphamide (4 or 7 g/m 2 ) (n = 17) or G-CSF alone (10 g/kg/day) (n = 6). PBPC collections were started when circulating CD34 + cells were у20/l in the CY+G-CSF group and on day +5 of G-CSF administration in the G-CSF group. Apheretic procedures were performed using a Cobe-Spectra continuous flow cell separator (Cobe Laboratories, Lakewood, CO, USA).
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Table 2
Recovery of committed progenitor cells 
Cryopreservation procedure
Leukapheresis products (150-190 ml buffy-coat cells in autologous plasma) were washed twice (2500 r.p.m., 15 min) with phosphate-buffered saline (PBS; Gibco, Grand Island, NY, USA) without Ca ++ and Mg ++ and resuspended in a 20% solution of ice-cold HSA (Pharmacia, Uppsala, Sweden). After counting, the volume of cell suspension was adjusted with HSA to achieve a cell concentration ranging from 80 × 10 6 to 400 × 10 6 per ml. Then, the cells were diluted 1:1 with ice-cold cryoprotectant solution (PBS (80%, v/v) and DMSO (20%, v/v) (Tera Pharmaceuticals, Buena Park, CA, USA)) to give a final concentration of 10% HSA and 10% DMSO with nucleated cell concentrations ranging from 40 to 200 × 10 6 per ml. Cell suspensions were then rapidly transferred into either cryovials (Nalge Nunc International, Naperville, IL, USA), to be used for research purposes ('small scale freezing'), or freezing bags (NPBI, Emmer-Compascuum, The Netherlands), to be used for clinical purposes ('large scale freezing'). Both cryovials or freezing bags were then placed at −80°C for 24-48 h. Cryopreserved blood cell transplants were subsequently stored in a −140°C mechanical freezer (Cryostar, Queue Systems, Brussels, Belgium) equipped with a liquid nitrogen rescue system until reinfusion.
Thawing procedure
Cryopreserved cells were thawed by rapid immersion into a 37°C water bath. Cells to be reinfused were injected intravenously into patients by a central venous catheter. Aliquots of cells to be assayed for progenitor cell contents were quickly transferred into 50 ml tubes and stepwise 
CFU-Mix, BFU-E, CFU-GM assay
The assay for multipotent CFU-Mix, erythroid BFU-E, and granulocyte-macrophage CFU-GM was carried out as described elsewhere. 15 Briefly, fresh or thawed nucleated cells (1 to 5 × 10 4 ) were plated in 35-mm Petri dishes in 1 ml aliquots of IMDM containing: 30% FBS; 10 -4 m 2-mercaptoethanol (Gibco), and 1.1% (w/v) methylcellulose (Stem Cell Technologies). Cultures were stimulated with interleukin-3 (10 ng/ml; Sandoz, Basel, Switzerland), granulocyte colony-stimulating factor (10 ng/ml; Amgen, Thousand Oaks, CA, USA), granulocyte-macrophage colony-stimulating factor (10 ng/ml, Sandoz) and erythropoietin (3 U/ml, Amgen). Progenitor cell growth was evaluated after 14-18 days of incubation (37°C, 5% CO 2 ) in a humidified atmosphere. Four dishes were set up for each individual data point per experiment. CFU-Mix, BFU-E and CFU-GM were scored from the same dish according to previously published criteria. 16 
LTC-IC assay
The long-term culture-initiating cell (LTC-IC) assay was performed according to Sutherland et al. 17 Briefly, test cell (5-8 × 10 6 nucleated cells) suspension was seeded into cultures containing a feeder layer of irradiated (8000 cGy) , kindly provided by Dr C Eaves, Terry Fox Laboratories, Vancouver, Canada) engineered by retroviral gene transfer to produce human IL-3 and human G-CSF. 18 Test cells were resuspended in complete medium consisting of alpha-medium (Gibco) supplemented with FBS (12.5%), horse serum (12.5%), l-glutamine (2 mm), 2-mercaptoethanol (10 -4 m), inositol (0.2 mm), folic acid (20 m) and freshly dissolved hydrocortisone (10 -6 m). Cultures were fed weekly by replacement of half of the growth medium containing half of the nonadherent cells with fresh complete medium. After 5 weeks in culture, nonadherent cells and adherent cells harvested by trypsinization were pooled, washed, and assayed together for clonogenic cells in standard methylcellulose cultures at an appropriate concentration. The total number of clonogenic cells (ie CFU-Mix plus BFU-E plus CFU-GM) present in 5-week-old LTC provides a relative measure of the number of LTC-IC originally present in the test suspension. 19 Absolute LTC-IC values were calculated by dividing the total number of clonogenic cells by 4, which is the average output of clonogenic cells per LTC-IC, according to limiting dilution analysis studies reported by others. 20 
Statistical analysis
Four plates were scored for each data point per experiment and the results were expressed as the mean ± 1 standard error of the mean (± s.e.m.). Statistical analysis was performed with the statistical package Statview (BrainPower, Calabasas, CA, USA) run on a Macintosh 6300 personal computer (Apple Computer, Cupertino, CA, USA). The Student's t-test for paired or unpaired data (two-tail) was used where appropriate to test for significance of differences between samples. Correlation coefficients were obtained for analysis of the effect of storage time at −140°C on the percentage recovery of hematopoietic progenitors.
Results
The effects of uncontrolled-rate cryopreservation on blood progenitors were investigated in 23 patients undergoing PBPC mobilization for therapeutic purposes. Since samples from five patients (cases 2, 10, 13, 14, 15) were studied on two separate occasions, a total of 28 samples could be analyzed. Ten samples (cases 1-9) were obtained from small scale freezing procedures performed in cryovials, whereas 18 samples (cases 10-23) were obtained from 501 Table 5 Hematopoietic recovery following high-dose chemotherapy and reinfusion of PBPC cryopreserved with uncontrolled-rate freezing large scale freezing procedures performed in freezing bags. An average time of 1.5 h, including washings, cell counting and media preparation, was required to cryopreserve blood cells. Thawed samples were analyzed for cell viability by trypan blue dye exclusion, recovery of nucleated cells by cell counting, and recovery of primitive and committed hematopoietic progenitors by long-and short-term cultures, respectively. The mean (± s.e.m.) storage time (−140°C) of cryovials and bags was 344 ± 40 and 299 ± 57 days, respectively ( Table 1 ). The mean cell viability of thawed samples was 91 ± 1%, with no difference being evident by comparing small and large scale freezing. As shown in Table 1 , P р 0.006) with values of cell recovery which were higher for bags than for vials (81 ± 2% vs 61 ± 7%, P р 0.001).
Despite the significant nucleated cell loss associated with thawing, the growth of committed progenitors was substantially unaffected by the freezing-thawing procedure. As shown in Table 2 , with the exception of a significant CFUMix growth reduction after small scale freezing, no other statistical evidence of colony growth reduction could be detected after small or large scale freezing. Mean recoveries for CFU-Mix, BFU-E and CFU-GM ranged from 60 ± 29% to 134 ± 15% and, despite the low recovery of CFU-Mix cryopreserved in cryovials, no statistical difference was evident when small scale and large scale freezing were compared (Table 2) .
To further characterize the functional activity of cryopreserved PBPC, the growth of primitive progenitors capable of initiating and sustaining hematopoiesis in long-term culture (LTC-IC) was evaluated in samples freezing on a small (n = 5) and large scale (n = 9) basis. Table 3 shows that post-freezing values were not different as compared to prefreezing values, with mean LTC-IC recoveries for small and large scale freezing of 262 ± 101% and 155 ± 27% (P = 0.2), respectively. Post-freezing recoveries of primitive and committed progenitors were not influenced by storage duration in a mechanical freezer at −140°C.
Progenitor cell recovery calculated on a per number basis, ie according to the number of plated cells (Tables 2 and 3) , may be affected by a selective cell loss induced by freezing and thawing procedures and may not be a reliable parameter for clinical purposes. Therefore, in 14 out of 23 patients who underwent high-dose chemotherapy and PBPC reinfusion, the pre-and post-freezing absolute numbers of hematopoietic progenitors cryopreserved in bags for clinical purposes were compared. As shown in Table 4 , a significant reduction was detected for CFU-Mix (11 vs 7.4 × 10 ) could be demonstrated. When these patients were reinfused with uncontrolled-rate cryopreserved PBPC, the mean number of days to reach 1 × 10 9 /l white blood cells and 50 × 10 9 /l platelets were 9 and 13, respectively (Table 5) .
Discussion
Mobilized PBPC are increasingly used to reconstitute hematopoiesis in patients undergoing high-dose chemoradiotherapy. 21 PBPC collections comprise a heterogeneous population containing pluripotent stem cells, committed progenitors, maturing precursors as well as mature cells and can be harvested in steady state, after chemotherapeutic conditioning, growth factor priming, or both. 22, 23 Randomized as well as non-randomized studies comparing engraftment after mobilized PBPC with recovery after marrow autografting have confirmed the beneficial effect on neutrophil and platelet engraftment and have shown that the accelerated hematological recovery can be associated with a number of clinical benefits, including a reduction of platelet transfusions and shorter hospital stay. 21, 23, 24 The increasing clinical use of blood cell transplants demands methodological improvements aimed at cost reduction and facilitation of routine freezing procedures. The cooling of hematopoietic cells to temperatures of 0°C to 4°C provides adequate conditions for short-term storage (12-36 h) . [25] [26] [27] [28] [29] However, according to current therapeutic strategies, virtually all autologous blood cell transplants require to be cryopreserved in view of the need for mid-or long-term storage. Optimal cryopreservation and storage protocols which either prevent or limit the functional damage of hematopoietic cells have not yet been defined. Ice crystal formation during cooling is the primary cause of cell damage. Intracellular ice crystal formation at rapid rates of cooling or extracellular ice crystal formation at slower rates of cooling result in loss of cell viability due to membrane rupture and cellular dehydration. The use of cryoprotectants decreases ice formation and reduces the phenomenon known as 'thermal shock'. Cryoprotectants act by lowering the freezing temperature of the medium, thereby reducing the proportion of water incorporated into ice and the extent of cellular dehydration. No standard cryoprotecting mixture is accepted by all transplant programs. Since DMSO penetrates cells rapidly and avoids intracellular freezing by preventing a substantial increase in the external osmotic pressure and reducing ice crystal formation, it has been preferentially used as a standard cryoprotective agent. Several investigators 30, 31 use HES as an extracellular cryoprotectant to prevent post-thawing macroscopic clumping. HSA, plasma or serum are also added as extracellular cryoprotectants. 32 Recently, the cryopreservation of PBPC with the plasma expander oxypolygelatine instead of human serum protein has been shown to be associated with optimal post-thawing progenitor cell recovery and marrow reconstituting function. 33, 34 In the present study, we report our experience of cryopreserving mobilized blood in DMSO and HSA using an uncontrolled-rate freezing procedure followed by storage in a mechanical freezer (−140°C). Our freezing procedure was applied to both cryovials, containing up to 203 × 10 6 cells per ml, and bags, containing up to 100 × 10 6 cells per ml. Analysis of PBPC cryopreserved in bags for clinical purposes revealed that following a mean storage of 300 days, our uncontrolled-rate freezing procedure was indeed associated with a significant reduction of nucleated cells, but no relevant detrimental effect was evident either in vitro, on the post-thawing recovery of primitive and committed progenitors, or in vivo, on the capacity of reconstituting marrow function. 6, 8, 35 These findings suggest that the freezing-thawing procedure results in a selective loss of precursor and mature cells in the absence of substantial damage on progenitor cell compartments. The only exception was represented by a significantly decreased recovery of CFUMix progenitors. Damage of multipotent CFU-Mix might be related to either a peculiar sensitivity of these progenitors to the 'thermal shock', or a higher requirement of growth factors to allow an optimal CFU-Mix growth. Indeed, the almost complete LTC-IC recovery achieved by our cryopreservation method strongly suggests that this procedure allows optimal freezing conditions for primitive hematopoietic cells with reconstituting capacity. This is further demonstrated by the prompt hematopoietic recovery achieved in our patients following high-dose chemotherapy.
Using a controlled-rate freezing procedure, Douay et al 36 reported deficient CFU-GM and BFU-E recoveries in cryovials as compared to bags, due to a quicker freezing rate occurring in the former. Our uncontrolled-rate freezing procedure applied to PBPC cryopreserved in cryovials resulted in a significant growth decrease (6 vs 1.7 per 5 × 10 4 cells) and low recovery (60%) of CFU-Mix, but not BFU-E, CFU-GM and LTC-IC. Since the present study was not aimed at comparing the progenitor cell recovery from paired samples cryopreserved in bags or vials, and is also biased by a significantly higher cell concentration in vials than bags, no definitive conclusion can be reached concerning the freezing efficiency of uncontrolled-rate cryopreservation on small vs large scale samples. In addition, whether controlled-rate freezing would have resulted in better progenitor cell recoveries than uncontrolled-rate freezing remains to be investigated by means of appropriately designed study.
The main disadvantage of uncontrolled-rate freezing might be the lack of a record documenting the cooling rate. Indeed, satisfactory cooling rates have been reported by placing PBPC at −80°C. 6, 8, 30, 35 No requirement for a controlled-rate device and reduced requirement of time and personnel are the main advantages of uncontrolled-rate freezing which translate in markedly decreased labor, costs and time related to PBPC processing.
In conclusion, the methodology described here allows optimal post-thawing recovery of primitive progenitors as well as committed progenitors and is associated with prompt hematopoietic recovery following high-dose chemotherapy. In addition, this methodology is simple, fast and reproducible, and avoids the preparation of autologous plasma or serum thus facilitating the routine cryopreservation of blood cell transplants.
